Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation.

Nishiyama, Keisuke; Sugimoto, Toshitsugu; Kaji, Hiroshi; Kanatani, Masanori; Kobayashi, Tatsuya; Chihara, Kazuo

doi:10.1210/endo.137.1.8536635

Cited by 84 publications

(53 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Drugs with high molecular weight cannot easily permeate through skin. Sometimes adhesives may not adhere well to all types of skin and maybe uncomfortable to apply (Nishiyama et al, 1996;Hsu et al, 2006).…”

Section: Side Effects Of Bps Therapymentioning

confidence: 99%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

Context: Bisphosphonates (BPs) are widely used for prevention and treatment of osteoporosis. BPs are known as gold standard for osteoporosis (OP) treatment due to their positive results in clinical studies. But some serious side effects are associated with BPs like gastrointestinal adverse effect i.e. esophagitis and ulcer of esophagus. Oral bioavailability (BA) of BPs ranges from 0.6 to 1% due to poor absorption through gastrointestinal tract (GIT). Objective: The main objective of this review is to explore the role of novel drug delivery systems (DDSs) for the delivering of BPs and minimizing the drawbacks associated with them. Methods: The current review is focusing on classification, mechanism of action, and limitations of BPs, and is also dwelling on the use of novel DDSs like nanoparticles, liposomes, topical, transdermal systems, implants, bisphosphonate osteotropic DDS (BP-ODDS), microspheres, and calcium phosphate cements (CPCs) for BPs. This review also gives a critically reviewed compilation of the various in vitro and in vivo studies conducted till date. Conclusion: On the basis of the exhaustive literature, it has been found that the novel DDS minimizes the side effects associated with BPs and enhances the BA. The advance drug delivery has a greater impact on reducing the undesirable effects and increasing the BA of BPs.

show abstract

Section: Side Effects Of Bps Therapymentioning

confidence: 99%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The presence of a functionally active specific IGF-Ir on mature osteoclasts supports a role for IGF-I in the activation of mature osteoclasts through the direct stimulation of local transmembrane receptors (Hou et al, 1997;Middleton et al, 1995). A binding site for IGF-I has been reported on hematopoietic blast cells (Nishiyama et al, 1996), which implies that IGF-I may directly stimulate the recruitment and formation of osteoclasts. It has been shown that IGF-I supports the activation and formation of osteoclasts and that osteoblasts mediate IGF-I-stimulated formation of osteoclasts (Slootweg et al, 1992;Mochizuki et al, 1992;Hill et al, 1995).…”

Section: Discussionmentioning

confidence: 64%

“…However, GH is able to stimulate mouse osteoclast-like cell formation from hemopoietic blast cells supported by GM-CSF (Nishiyama et al, 1996). The PCR product of mouse GHr was detected in these hemopoietic blast cells supported by GM-CSF, indicating a possible mechanism whereby GH may interact with osteoclast precursors and stimulate osteoclast-like cell formation (Nishiyama et al, 1996;Chihara and Sugimoto, 1997). 0.98 ± 0.14 4.2 ± 1.1 0.4 ± 0.4 2.0 ± 1.8 tl/tl + CSF-1 4 2.11 ± 0.3 8.7 ± 2.0*** 1.6 ± 1.2* 2.6 ± 0.9 * p < 0.05; *** p < 0.001.…”

Section: Discussionmentioning

confidence: 98%

“…In vivo administration of hGH leads to an activation of osteoclasts and osteoblasts (Vandeweghe et al, 1993;Kassem et al, 1994;Brixen et al, 1995). It is possible that GH affects osteoclastic bone resorption by directly acting on mature osteoclasts and their precursor cells or by indirectly acting on them via nonosteoclastic cells, such as stromal cells (including osteoblasts) (Nishiyama et al, 1996;Guicheux et al, 1998). The mechanism of action of GH on bone resorption mediated by stromal cells may be through an increase in IGF-I production and/or activity (Nishiyama et al, 1996;Rousselle et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Growth Hormone Receptor and Insulin-like Growth Factor-I Immunoreactivity in Osteoclast-like Cells During Tooth Eruption in the Toothless (Osteopetrotic) Rat Following Treatment with Colony-Stimulating Factor-1

Symons

Weerakoon

Marks

2003

Crit Rev Eukaryot Gene Expr

View full text Add to dashboard Cite

ABSTRACT:In the toothless (tl/tl) osteopetrotic rat, teeth form but fail to erupt. Treatment of tl/tl rats with colony-stimulating factor-1 (CSF-1) activates bone resorption by osteoclasts, permits tooth eruption, and upregulates the immunoreactivity of bone marrow mononuclear cells to growth hormone receptor (GHr) and insulinlike growth factor (IGF)-I. This study examined the distribution of tartrate-resistant acid phosphatase (TRAP) and immunoreactivity for GHr and IGF-I in osteoclast-like cells located on the alveolar bone margin, adjacent to the lower first molar crown, in 14-day-old normal and tl/tl rats, following treatment with CSF-1. Osteoclast-like cells demonstrated a positive reaction for TRAP, GHr, and IGF-I in all groups. However, in tl/tl tissue, osteoclast-like cells were generally negative for GHr. There was no significant difference in the total number of TRAP-, GHr-, and IGF-I-positive osteoclast-like cells on the adjacent bone margin in normal, normal treated with CSF-1, and tl/tl rats. CSF-1 treatment of the tl/tl rat significantly increased the total number of osteoclast-like cells, which were positive for TRAP (p < 0.001), GHr (p < 0.05) and IGF-I (p < 0.01).

show abstract

“…In fact, the hormone induces an increase in the markers of osteoblast differentiation, such as osteocalcin and alkaline phosphatase (Kassem et al 1993). GH is able to stimulate osteoclastic bone resorption through direct and indirect actions on osteoclast differentiation and through indirect activation of mature osteoclasts, possibly through local IGF-I/-II (Nishiyama et al 1996, Kanatani et al 2000.…”

Section: Introductionmentioning

confidence: 99%

Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells

Mrak

Villa²,

Lanzi

et al. 2007

Journal of Endocrinology

View full text Add to dashboard Cite

It is presently thought that osteoprotegerin (OPG) is a cytokine involved in the regulation of osteoblast/osteoclast crosstalk and maintenance of bone mass. Recent studies showed that GH replacement therapy in GH-deficient patients was able to induce a significant increase of OPG in the plasma, as well as in the cortical and the trabecular bone. In order to determine whether GH could directly modulate OPG secretion, the effect of GH on human osteoblast-like cells (hOB) in primary culture was studied. After detecting the presence of the mRNA for the GH receptor (GHR) by RT-PCR, hOB were exposed to increasing concentrations of GH, from 0 . 1 to 25 ng/ml, for 24 h. The results showed that GH exposure was able to stimulate OPG secretion in a concentration-dependent manner. In addition, the OPG mRNA levels were increased, indicating that the hormone has a stimulatory effect on gene expression. The stimulatory effect on OPG expression and production was prevented by exposing the cells to tyrphostin AG490 (10 mM), an inhibitor of Janus kinase 2, which is one of the kinases involved in the intracellular pathway activated by the binding of GH to its receptor. Similar results were obtained when the cells were exposed to a receptor antagonist of GH, pegvisomant at 50 nM. GH exposure neither induced an increase in IGF-I expression nor secretion in hOB. These results suggest that the stimulation of OPG production induced by GH in hOB is specific and receptor mediated and further support the view that GH is able to modulate bone remodeling by directly influencing osteoblast-osteoclast crosstalk.

show abstract

Stimulatory effect of growth hormone on bone resorption and osteoclast differentiation.

Cited by 84 publications

References 16 publications

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Growth Hormone Receptor and Insulin-like Growth Factor-I Immunoreactivity in Osteoclast-like Cells During Tooth Eruption in the Toothless (Osteopetrotic) Rat Following Treatment with Colony-Stimulating Factor-1

Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells

Contact Info

Product

Resources

About